AIC, a division of AIS Healthcare, has announced the addition of YIMMUGO, a new immunoglobulin therapy manufactured by Kedrion Biopharma, for patients aged two years and older with primary humoral immunodeficiency. This treatment received FDA approval in June 2024 and is now accessible at every AIC location nationwide.
Health Technology Insights: BETA Healthcare Group Maintains its “A” Rating from AM Best Company
The infusion teams at AIC, accredited at a national level, work closely with doctors to deliver personalized infusion services either at home or in specialized infusion centers. Adding YIMMUGO to their portfolio strengthens AIC’s commitment to offering advanced treatment options for patients living with primary immunodeficiency.
Jud Hall, President of AIC, expressed enthusiasm about expanding their range of immunoglobulin therapies, highlighting the importance of this new option. Stan Singley, AIC’s Vice President of Trade and Procurement, noted that partnering with Kedrion Biopharma as part of a specialty pharmacy limited distribution network ensures patients across the country have exclusive access to this highly purified intravenous immunoglobulin treatment.
Health Technology Insights: SonderMind Unveils AI Tools to Improve Mental Health Care
Patients receiving care at AIC benefit from round-the-clock support provided by a dedicated team that includes clinical pharmacists, infusion nurses, registered nurse clinical review specialists, and patient access coordinators. This team-based approach ensures consistent care and assistance throughout the entire treatment journey.
For healthcare providers, AIC offers more than just specialty pharmacy services. The company maintains contracts with multiple immunoglobulin suppliers, including Kedrion Biopharma, helping ensure that prescribed treatments remain in stock. AIC also assists patients, insurance companies, and medical offices in obtaining necessary insurance authorizations and approvals, simplifying the process for everyone involved.
Both AIS Healthcare and the AIC division hold dual accreditation from URAC and the Accreditation Commission for Health Care. These credentials underline their commitment to maintaining high-quality standards and set them apart from other infusion service providers.
Health Technology Insights: Gareth Morgan Named President of Qpex Biopharma, Inc.
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
